Background:
- One way tumors are able to grow is by forming new blood vessels that supply it with
nutrients and oxygen.
- Vandetanib (ZD6474) is an experimental drug that blocks certain proteins on the surface
of tumor and blood vessel cells that are involved with the formation of new blood
vessels.
- Blocking these proteins may prevent the tumor cells or blood vessels from continuing to
grow.
Objectives:
- To determine whether vandetanib can cause tumors to shrink or stabilize in patients with
advanced kidney cancer.
- To determine how vandetanib may work in people with kidney cancer and to develop tests
that may be helpful in studying kidney cancer.
Eligibility:
-Patients 18 years of age or older with advanced clear cell kidney cancer whose disease has
worsened after treatment with one or more of the following drugs: sunitinib, sorafenib,
interleukin-2 and temsirolimus; or patients who have had to stop treatment with these drugs
due to unacceptable side effects; or patients who are unable to receive standard treatment.
Design:
- Patients take a vandetanib pill once a day in 28-day cycles.
- Patients are followed in the clinic every 2 weeks during the first month of treatment
and then every 4 weeks for a physical examination, blood and urine tests,
electrocardiogram and a review of any drug side effects.
- Patients have imaging scans (computed tomography (CT) or magnetic resonance imaging
(MRI)) about every 8 weeks to monitor tumor growth. MRI scans are also done to look at
tumor blood flow when treatment begins, 24 hours after the first dose of treatment, and
again about 4 and 8 weeks after starting treatment
- Optional tumor biopsies (surgical removal of a sample of tumor tissue) may be done
before starting vandetanib treatment and after 4 weeks of treatment to look for drug
effects on the tumor.